Top Nutrition Coaching is fully dedicated to providing its readers with transparent, accurate, and compassionate information that applies to individuals from every demographic. Our nutritionists adhere to specific guidelines when creating content to ensure that all published materials are most advantageous to our readers. Top Nutrition Coaching has a no-tolerance policy regarding plagiarism.
All materials published by Top Nutrition Coaching adhere to the criteria outlined below:
Ozempic’s highest dose led to about 15 pounds of average weight loss in clinical trials, while the widely cited 15% figure comes from a higher semaglutide dose. Here’s what the research shows by dose, why results vary, and how nutrition support fits in.
You may have heard that Ozempic (semaglutide) helps you lose about 15% of your body weight. But that number comes from a study using semaglutide 2.4 milligrams (mg) weekly, higher than Ozempic’s maximum dose of 2 mg. In another trial, adults with type 2 diabetes taking Ozempic’s highest approved dose lost an average of 15 pounds over 40 weeks.
So, what can you realistically expect? Because studies report different results, it’s not always easy to tell. That’s why we’ll walk you through what the research found, why weight loss varies, and what could happen if you stop taking Ozempic.
In the SUSTAIN FORTE trial, adults with type 2 diabetes taking Ozempic’s highest approved dose of 2 mg weekly lost about 15 pounds (6.9 kilograms or kg) on average over 40 weeks. Those taking 1 mg lost about 13 pounds (6.0 kg). These results reflect weight loss while staying on treatment.
And now the caveat.
The widely cited 15% figure comes from a different study. In STEP 1, adults without diabetes taking semaglutide 2.4 mg weekly lost an average of 14.9% of their starting weight over 68 weeks, with nearly one-third losing at least 20%.
Why Ozempic Results Differ From the 15% Headline
The two studies most often cited for semaglutide weight loss
| SUSTAIN FORTEOzempic Doses | STEP 1Wegovy-Level Dose | |
|---|---|---|
| Weekly Dose | 1 mg or 2 mg | 2.4 mg |
| Who Was Studied | Adults with type 2 diabetes | Adults without diabetes |
| Length | 40 weeks | 68 weeks |
| Average Weight Loss | About 15 lb (6.9 kg) on 2 mg; about 13 lb (6.0 kg) on 1 mg | 14.9% of starting weight |
Sources: SUSTAIN FORTE, Lancet Diabetes & Endocrinology; STEP 1, New England Journal of Medicine. SUSTAIN FORTE results reflect people who stayed on treatment. Individual results vary.
STEP 1 used a higher dose, lasted longer, and included people without diabetes, who tend to lose more weight on semaglutide. That's why its findings aren’t exactly comparable to those from Ozempic’s approved doses.
Of course, individual results vary, even among people taking the same dose.
Ozempic and Wegovy are both made by Novo Nordisk and contain the same active ingredient, semaglutide.
The main difference is what they’re approved to treat: Ozempic is primarily for type 2 diabetes, while Wegovy is approved for weight management. Licensed prescribers can also legally prescribe Ozempic for weight loss in people without diabetes, even though the U.S. Food and Drug Administration (FDA) hasn’t approved it for that purpose. This is called off-label use.
Compounded and research-grade semaglutide products, on the other hand, aren’t FDA-approved, so results from Ozempic and Wegovy studies may not apply to them. Talk with your prescriber about which medication and dose may be best for you.
The FDA prescribing information identifies that Ozempic is approved to improve blood sugar control in adults with type 2 diabetes and reduce certain cardiovascular and kidney risks.
Treatment starts at 0.25 mg weekly for four weeks, then increases to 0.5 mg. If needed, the dose can increase to 1 mg and then 2 mg, with at least four weeks between increases. Starting with a low dose helps reduce digestive side effects, so weight loss may be modest during the first month.
The 2.4 mg dose is Wegovy’s usual maintenance dose, although treatment starts much lower. A higher 7.2 mg dose (Wegovy HD) was also approved in 2026 for some adults who need additional weight loss. Wegovy’s standard injection schedule gradually increases the dose, typically every four weeks, from 0.25 mg to 0.5, 1, and 1.7 mg before reaching 2.4 mg weekly.
The SUSTAIN trials mostly studied blood sugar control in adults with type 2 diabetes, but also included weight loss. Participants generally lost 8 to 15 pounds over 30 to 56 weeks, depending on the dose and referenced study.
Many participants had poorly controlled blood sugar despite taking medications such as metformin, so results may differ for others. Ozempic also follows a gradual semaglutide dosing and titration schedule, meaning the dose increases over time to help reduce side effects.
Ozempic 1 mg vs. 2 mg in SUSTAIN FORTE
Adults with type 2 diabetes, after 40 weeks
1 mg weekly
2 mg weekly
Average Weight Loss
1 mg
13 lb
2 mg
15 lb
Average HbA1c Reduction
1 mg
1.9 points
2 mg
2.2 points
Source: Frias JP, et al., Lancet Diabetes & Endocrinology. Results reflect people who stayed on treatment. Weight values rounded from 6.0 kg and 6.9 kg. Individual results vary.
Adults taking 1 mg weekly in the SUSTAIN FORTE trial lost an average of 13 pounds (6.0 kg) over 40 weeks. Their hemoglobin A1c (HbA1c), a measure of average blood sugar over two to three months, also fell by about 1.9 percentage points.
In the STEP 2 trial, adults with type 2 diabetes taking the same dose lost an average of 6.9% of their starting weight over 68 weeks.
Because 1 mg may provide enough blood sugar control, you may not need to increase the dose. Your prescriber can help decide based on your treatment goals.
At 2 mg weekly, participants lost an average of 15 pounds (6.9 kg) over 40 weeks, about 2 pounds more than those taking 1 mg.
HbA1c fell by 2.2 percentage points, compared with 1.9 at 1 mg. Both doses had similar safety profiles, with digestive side effects common, especially at the higher dose.
In other words, doubling the dose added only modest weight loss and blood sugar benefits. If you’re not seeing the results you’d hoped for, talk with your prescriber about whether changing your dose makes sense rather than doing it on your own.
The STEP trials studied how much weight people lost while taking semaglutide 2.4 mg weekly, a higher dose than Ozempic’s 2 mg maximum. After 68 weeks, people without diabetes had lost an average of 14.9% of their starting weight, while those with type 2 diabetes lost 9.6%. Participants also received advice on healthy eating and exercise during the studies.
STEP 1 included 1,961 adults without diabetes who had obesity or overweight with a weight-related condition. About three-quarters were women.
After 68 weeks, average weight loss was 14.9% with semaglutide versus 2.4% with placebo. That’s roughly 33 pounds for someone starting at 220 pounds.
How Many People Reached Each Weight Loss Level in STEP 1
Adults without diabetes, after 68 weeks (n = 1,961)
Source: Wilding JPH, et al., New England Journal of Medicine. Percentages are rounded. All participants also received lifestyle counseling. Individual results vary.
About 86% lost at least 5%, 69% lost at least 10%, 51% lost at least 15%, and 32% lost 20% or more.
STEP 2 followed 1,210 adults with overweight or obesity and type 2 diabetes for 68 weeks. Participants taking 2.4 mg weekly lost an average of 9.6% of their starting weight, compared with 6.9% for those taking 1 mg and 3.4% for those taking a placebo.
Not everyone lost the same amount, though. About 69% of people taking 2.4 mg lost at least 5% of their starting weight, compared with 29% of those taking a placebo.
Overall, people in STEP 2 lost less weight than those in STEP 1. Type 2 diabetes and certain medications, such as insulin, can make weight loss more difficult, although differences between the study groups may also play a role. Still, improvements in blood sugar and other health measures matter, even if the scale doesn’t change as much.
STEP 5 looked at whether weight loss lasted beyond the 68 weeks reported in many trials. After 104 weeks, adults without diabetes taking semaglutide 2.4 mg lost an average of 15.2%, versus 2.6% with placebo.
Most weight loss happened during the first year, leveling off around week 60. Participants then maintained much of that loss through year two while continuing medication and lifestyle support.
In STEP 1, some participants lost little or no weight, while others lost more than 25% of their starting weight, despite taking the same semaglutide dose. About 14% lost less than 5%, while nearly one-third lost at least 20%.
An analysis of clinical trial data found that sex, starting weight, and weight changes during the first 16 weeks helped predict longer-term weight loss.
Still, losing weight slowly at first doesn’t mean you won’t make more progress as your dose increases. It can take several months to gauge how well semaglutide works for you.
Clinical trials report weight loss as a percentage since people start treatment at varying weights. For instance, losing 10% of your body weight means losing 19 pounds if you start at 190 pounds, or 25 pounds if you start at 250.
To calculate your percentage, divide the pounds lost by your starting weight and multiply by 100. For example, losing 18 pounds from 190 is a 9.5% reduction.
Weight Loss Percentage Calculator
Enter your starting and current weight to see the percentage you’ve lost.
This calculator is for general information only and isn’t medical advice. Your prescriber or registered dietitian can help you interpret your progress in the context of your health.
Percentages also help put health benefits into perspective. Losing just 5% to 10% of your starting weight can improve blood pressure, cholesterol, and blood sugar, according to the Centers for Disease Control and Prevention (CDC). Greater losses may also improve sleep apnea and joint pain.
So, while 18 pounds may sound modest compared with someone else’s 40, losing nearly 10% is meaningful and worth celebrating! Reflect on your health markers and how you feel and function, not just the number on the scale.
The biggest factors affecting weight loss on semaglutide are your dose and whether you have type 2 diabetes. Otherwise, results are fairly consistent across different groups, although individual responses vary.
As the STEP trials showed, adults without diabetes tend to lose more weight on semaglutide than those with type 2 diabetes.
Women tend to lose a greater percentage than men, although the difference varies across studies. STEP subgroup analyses also found weight loss across ages, sexes, racial and ethnic groups, starting weights, body mass index (BMI) categories, and blood sugar levels.
People who have had type 2 diabetes for longer or take certain diabetes medications, such as insulin or sulfonylureas, may lose less weight on semaglutide. However, they can still lose weight.
Staying on an effective, tolerable dose is one of the strongest factors associated with greater weight loss. Your prescriber can help determine the right dose, while a registered dietitian can help manage digestive side effects that make treatment difficult.
Adequate protein and regular strength training can help preserve muscle while losing weight. Quality sleep may help manage hunger and curb cravings, while limiting alcohol reduces extra calories and digestive symptoms like nausea.
These habits can support treatment, but cost, insurance coverage, and side effects also affect whether someone can stay on medication.
When you lose weight on semaglutide, you’re often losing more than body fat. Research on glucagon-like peptide-1 (GLP-1) and related medications suggests that roughly 26% to 40% of weight loss may be lean tissue, including muscle, water, and other nonfat tissue.
Losing muscle can affect your strength and mobility. It can also slightly reduce how many calories your body burns at rest, since each kilogram of skeletal muscle burns about 13 calories per day.
Water weight can change, too. When your body uses stored carbohydrates (called glycogen), it releases some of the water stored with them, which can temporarily lower your weight.
If you want to know whether you’re losing fat or muscle, the scale alone won’t tell you. Body composition tools, including a dual-energy X-ray absorptiometry (DEXA) scan, can estimate both.
“The gold standard for determining whether or not a patient is losing fat while building muscle in a weight loss plateau during GLP-1 treatment is a DEXA scan,” says Dr. Devon Allen, physician and medical contributor at Top Nutrition Coaching. “Prior to referring patients for a DEXA scan, however, I encourage them to use home assessment tools such as bioelectrical impedance analysis (BIA) or so-called ‘smart scales.’ These are convenient, reliable ways to track your progress. Another reliable tracking tool is a simple tape measure — follow body measurements weekly for objective data tracking. Additionally, paying attention to how your clothes fit is an old-fashioned but effective way to track your progress!”
Real-world weight loss is often lower than what clinical trials report. Side effects, medication costs, and insurance coverage can make it difficult to stay on treatment or reach a higher dose.
In a study of 7,881 adults prescribed semaglutide or tirzepatide, those who stayed on medication for at least a year lost an average of 11.9% of their starting weight. Those who stopped after three to 12 months lost 6.8%, while those who stopped within three months lost 3.6%.
Average Weight Loss After One Year in a Real-World Study
Adults prescribed semaglutide or tirzepatide (n = 7,881)
By How Long People Stayed on Treatment
Stayed on a Higher Maintenance Dose
SURMOUNT-1 trial result: 20.9% (tirzepatide 15 mg, 72 weeks)
Source: Gasoyan H, et al., Obesity. The trial line is for reference only; trial and real-world groups differ. Averages may not reflect individual results.
More than 20% stopped treatment within three months, and another 32% stopped between three and 12 months. More than 80% never reached a high maintenance dose. Among those who stayed on higher doses, average weight loss was 13.7% with semaglutide and 18.0% with tirzepatide, highlighting how semaglutide and tirzepatide compare.
Staying on treatment isn’t always easy, and side effects can be especially challenging. A registered dietitian can help you adjust what and how you eat to manage digestive symptoms and make treatment more manageable.
Weight regain is common after stopping semaglutide, partly because hunger can return as the medication’s effects wear off.
In the STEP 1 trial extension, participants regained about two-thirds of their lost weight within one year of stopping semaglutide 2.4 mg and structured lifestyle support. After initially losing an average of 17.3% of their starting weight, they regained 11.6 percentage points, leaving them about 5.6% below their starting weight. Blood pressure, cholesterol, and blood sugar also began returning toward pre-treatment levels.
Still, nearly half maintained at least 5% weight loss after a year. However, the study used a higher dose than Ozempic's maximum, and participants stopped both medication and lifestyle support.
Long-term medication may be needed to maintain weight loss. If you’re considering stopping Ozempic, talk with your prescriber about managing increased hunger and possible weight regain.
In a 12-month study, participants completing a remote program combining GLP-1 medication with nutrition and behavioral support lost an average of 17.1% with semaglutide and 22.1% with tirzepatide. These results are encouraging, though the study couldn’t isolate the benefits of coaching.
Still, semaglutide trials included nutrition, exercise, and behavioral support, so their results don’t reflect medication alone.
A registered dietitian can help manage side effects, meet nutritional needs despite reduced appetite, and preserve muscle. Between-session text or chat support also allows for adjustments as symptoms or your goals change.
Eating less can make it harder to meet your nutritional needs. Knowing what to eat and avoid while taking Ozempic can help, especially when you’re dealing with digestive side effects.
Focus on these three core areas:
You may need to pause or stop Ozempic because of insurance changes, medication shortages, or side effects. Since hunger often increases after stopping, a regular eating and exercise routine can help reduce those changes.
Try to eat enough protein and fiber, stay hydrated, strength train at least twice a week, and get consistent sleep. You may also need to adjust your portions or snacks as your appetite returns.
If you’ve missed several doses, talk with your prescriber before restarting. You may need to begin again at a lower dose.
These habits can help you stay healthy, although they may not prevent some weight regain.
Semaglutide can reduce appetite, but nutrition and strength training help support muscle, overall health, and lasting habits. Start by knowing your dose, tracking your weight trend and a health measure beyond the scale, and setting a realistic protein and exercise routine.
A registered dietitian can tailor your eating plan to your appetite, medications, diabetes status, lab results, and food preferences, while your prescriber guides medication changes.
Top Nutrition Coaching is in-network with Aetna, Anthem/Blue Cross Blue Shield, Cigna, and UnitedHealthcare, though coverage varies. Check whether your insurance covers a dietitian before booking.
For personalized guidance, work with a registered dietitian who can support your GLP-1 treatment. They can help you build an eating plan that fits your treatment and daily life.
Weight loss in the first month is usually modest. Ozempic starts at a low dose of 0.25 mg weekly to help reduce side effects, so many people see only small changes at first.
Weight loss often picks up over the first few months as the dose increases, though results vary widely from person to person. Many published estimates also come from studies using higher doses than Ozempic’s approved maximum.
No, Ozempic is FDA-approved for type 2 diabetes and certain related health risks, not weight management. It can be prescribed off-label for weight loss.
Both contain semaglutide, but they’re FDA-approved for different uses. Ozempic is mostly prescribed to treat type 2 diabetes, with a maximum dose of 2 mg weekly, while Wegovy is approved for weight management and typically uses a maintenance dose of 2.4 mg weekly, with a higher 7.2 mg dose also approved.
In SUSTAIN FORTE, adults with type 2 diabetes lost an average of 13 pounds at 1 mg weekly versus 15 pounds at 2 mg over 40 weeks.
People with type 2 diabetes generally lose less weight on semaglutide, possibly due to metabolic differences and medications such as insulin, though the reasons aren’t fully understood.
Weight loss on Ozempic may become noticeable within four to 12 weeks. It often starts gradually as the dose increases and continues over several months.
Weight loss may plateau after roughly 12 to 15 months, although this estimate comes from studies using 2.4 mg weekly, above Ozempic’s maximum dose.
Weight regain is common after stopping semaglutide. In a STEP 1 follow-up, participants regained about two-thirds of their lost weight within a year of stopping 2.4 mg weekly, but individual results vary.
Losing 20% is possible, but less common at Ozempic’s approved doses. In STEP 1, nearly one-third lost at least 20%, but participants took 2.4 mg weekly.
Studies suggest that roughly 26% to 40% of weight lost on semaglutide and related medications may be lean tissue, including muscle, water, and other nonfat tissue. Protein and strength training can help preserve muscle as you lose weight.
A registered dietitian can help manage side effects, meet nutritional needs, and preserve muscle. Combined medication and nutrition programs show promising results, but the added weight loss benefit of dietitian care alone isn’t certain.





